Lessons Learned from Open‐label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years

Abstract

Our clinical experience supports the urgent need for more data and refinements in interventions and outcome measurements for severe, malignant, and medication-refractory TS. Because TS is not an etiologically homogenous clinical entity, the inclusion criteria for DBS patients and the choice of brain targets will require more refinement.